ClinicalTrials.gg
CompletedNCT00784303Updated Apr 22, 2020Results posted

Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology

A Phase 2 interventional study of Lenvatinib (DTC Cohort) and Lenvatinib (MTC Cohort) in Thyroid Cancer, sponsored by Eisai Inc.. Completed at 42 sites in 6 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2020-04-22.

Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
117
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 17 studies testing lenvatinib in Thyroid Neoplasms — 6 open to participants now, 7 under way, none of them phase 3. lenvatinib · Thyroid Neoplasms.

Enrollment
6th of 17
117 · median 35
Started
2008
the only one that year
Phase 2
10 of 17
2 open now
Registered
1st of 17
by date
Lead sponsor
3 of 17
Eisai Inc.

Among the 17 studies testing lenvatinib in Thyroid Neoplasms, this one is the 6th largest by enrollment, is the only one that started in 2008, is one of 10 in phase 2, and was the 1st registered.

Thyroid Neoplasms

785 studies on the registry are indexed under Thyroid Neoplasms; 203 are open to participants now.

Browse Thyroid Neoplasms studies →

Open to participants now

6 of the 17 studies testing lenvatinib in Thyroid Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 151 Thyroid Neoplasms studies recruiting now, 95 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 36 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing lenvatinib in Thyroid Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and efficacy of oral lenvatinib in participants with medullary thyroid cancer (MTC) or radioiodine (131 I)-refractory/resistant differentiated thyroid cancer (DTC), unresectable differentiated thyroid cancers, stratified by Histology.

Read the detailed description

This study contained 3 Phases: the Pretreatment Phase, the Treatment Phase, and the Extension Phase. The Pretreatment Phase lasted no longer than 28 days. Informed consent was obtained and protocol eligibility and disease characteristics were established prior to treatment. The Treatment Phase consisted of a Treatment Period and a Follow-up Period. The Treatment Period of the Treatment Phase began at the time that the first participant began study drug administration and ended at the time when all participants enrolled completed 8 cycles of treatment or discontinued study treatment prior to the eighth cycle (ie, time of data cutoff for the primary study analysis [Primary Completion Date]). All participants then entered the Extension Phase. The Extension Phase consisted of a Treatment Period and a Follow-up Period. The Extension Phase began immediately after the Treatment Phase ended and included all participants that were either still receiving treatment or in follow-up. The time of data cutoff for the primary study analysis occurred when all subjects in the study completed 8 cycles of treatment or discontinued study treatment prior to the eighth cycle.

03

Conditions studied

  • Thyroid Cancer

Browse trials for

Keywords

  • Thyroid Cancer
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed diagnosis of medullary thyroid cancer (MTC) or differentiated thyroid cancer (DTC).
  2. meeting the following criterion:

    1. At least one lesion (greater than or equal to 1.5 cm in longest diameter for non-lymph nodes and greater than or equal to 2.0 cm in longest diameter for lymph nodes) which is serially and accurately measurable according to modified (RECIST) using either computed tomography (CT) or magnetic resonance imaging (MRI).
    2. Lesions that have had electron beam radiotherapy must show evidence of progressive disease based on modified RECIST to be deemed a target lesion.
  3. Evidence of disease progression by RECIST using site assessment of CT/MRI scans within 12 months (+1 month to allow for variances in patient scanning intervals) prior to study entry.
  4. DTC must be 131-I /resistant: never demonstrated 131-I uptake, progression despite 131-I uptake, or cumulative dose of 131-I of greater than 600 millicurie (mCi) (last dose given at least 6 months prior to study entry).
  5. Well controlled blood pressure prior to study entry.

Exclusion criteria

Exclusion criteria:

  1. Anaplastic thyroid carcinoma, thyroid lymphoma, mesenchymal tumors of the thyroid, to the thyroid.
  2. Brain or .
  3. Significant cardiovascular impairment (history of congestive heart failure, [NYHA] Class II, unstable angina or myocardial infarction within 6 months of study start, or serious cardiac arrhythmia).
  4. Marked baseline prolongation of /corrected QT (QTc) interval.
  5. Proteinuria greater than 1+ or greater than 30 mg in dipstick testing.
  6. Active hemoptysis (bright red blood of at least one-half teaspoon) in the 28 days prior to study entry.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
117 participants (actual)

Study arms

  • Experimental
    DTC cohort

    This arm will enroll participants with radioiodine (131 I)-refractory/resistant differentiated thyroid cancer.

    Drug: Lenvatinib (DTC Cohort)

  • Experimental
    MTC cohort

    This arm will enroll participants with medullary thyroid cancer.

    Drug: Lenvatinib (MTC Cohort)

Interventions

  • DrugLenvatinibStudies of LenvatinibLenvatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    24 mg lenvatinib (two 10 mg tablets and one 4 mg tablet) given orally, once daily, or 10 mg lenvatinib orally twice daily (20 mg total). Out of 58 participants in the DTC cohort, 56 participants received 24 mg lenvatinib once daily and 2 participants received 10 mg lenvatinib twice daily (total 20 mg daily), given continuously in 28-day treatment cycles.

    Also known as: E7080, LENVIMA

  • DrugLenvatinibStudies of LenvatinibLenvatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    24 mg lenvatinib (two 10 mg tablets and one 4 mg tablet) given orally, once daily given continuously in 28-day treatment cycles.

    Also known as: E7080, LENVIMA

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR was the percentage of participants with best overall response (BOR) of complete response (CR) and partial response (PR) based on modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 for target lesions using magnetic resonance imaging/computed tomography (MRI/CT) scans, as determined by independent imaging review (IIR). CR was defined as disappearance of all target lesions. PR was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of the longest diameter. ORR=CR+PR, was presented with 2-sided 95% confidence interval (CI) by the method of Clopper and Pearson.

    Time frame: From date of treatment start until disease progression, development of unacceptable toxicity, withdrawal of consent, participant's choice to stop study treatment, or up to data cutoff date 11 April 2011, for up to approximately 2 years 5 months

  2. Plasma Pharmacokinetics (PK): Steady State Area Under the Plasma Concentration Curve (AUC)

    Up to 9 samples per participant were obtained at specific time points. Plasma concentrations of lenvatinib were analyzed using standard analysis methods. Due to the sparse PK sampling in this study, the data were pooled with data from other Phase 1 studies conducted in participants with solid tumors for PK model development and covariate analysis. Individual exposure (steady state AUC) to lenvatinib in MTC and DTC subjects in this study was derived based on the individual predicted steady state AUC from the final PK model. Only data for participants taking 24 mg lenvatinib daily were reported (participants taking 20 mg lenvatinib daily were not included in this data set).

    Time frame: Cycle 1 Day 1 (predose and at 0.5 and 2 hours postdose), Cycle 1 Day 8 (predose), Cycle 2 Day 1 (predose and at 0.5 and 2 hours postdose), and Cycle 3 Day 1 (predose and at 2 hours postdose) (Cycle length= 28 days)

Secondary outcomes

  1. Change From Baseline in Free Thyroxine (T4)

    Blood samples to measure free T4 were collected at Screening (Baseline), Cycle 1 Day 15 (MTC cohort), Day 1 of Cycles 2 to 20, and Final Visit. Changes in free T4 concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included.

    Time frame: Day 1 or within 72 hours prior to Day 1 of Cycles 2 to 20, and Final Visit, up to data cutoff date 11 April 2011 (Cycle length= 28 days)

  2. Change From Baseline in Free Thyroid Stimulating Hormone (TSH)

    Blood samples to measure free TSH were collected at Screening (Baseline), Cycle 1 Day 15 (MTC cohort), Day 1 of Cycles 2 to 20, and Final Visit. Changes in free TSH concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included. For any free TSH result that was reported as \<0.008 mIU/L, 0.004 mIU/L was used for calculating summary statistics.

    Time frame: Day 1 or within 72 hours prior to Day 1 of Cycles 2 to 20, and Final Visit, up to data cutoff date 11 April 2011 (Cycle length= 28 days)

  3. Percent Change From Baseline in Concentrations of Thyroglobulin (DTC Only)

    Blood samples to obtain serum were collected at Cycle 1 Day 1 (Baseline), Day 1 of Cycles 2 to 19, Final Visit, and were analyzed for thyroglobulin concentration. Percent changes in thyroglobulin concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included.

    Time frame: Day 1 or within 72 hours prior to Day 1 of Cycles 2 to 19, and Final Visit, up to data cutoff date 11 April 2011 (Cycle length= 28 days)

  4. Percent Change From Baseline in Concentrations of Calcitonin (MTC Only)

    Blood samples to obtain serum were collected at Cycle 1 Day 1(Baseline), Day 1 of Cycles 2 to 20, Final Visit, and were analyzed for calcitonin concentration. Percent changes in calcitonin concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included.

    Time frame: Day 1 or within 72 hours prior to Day 1 of Cycles 2 to 20, and Final Visit, up to data cutoff date 11 April 2011 (Cycle length= 28 days)

  5. Percent Change From Baseline in Concentrations of Carcinoembryonic Antigen (CEA) (MTC Only)

    Blood samples were collected at Cycle 1 Day 1(Baseline), Day 1 of Cycles 2 to 20, Final Visit, and were analyzed for CEA concentration. Percent changes in CEA concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included.

    Time frame: Day 1 or within 72 hours prior to Day 1 of Cycles 2 to 20, and Final Visit, up to data cutoff date 11 April 2011 (Cycle length= 28 days)

  6. Change From Baseline in Concentrations of Cytochrome C (CytoC)

    Blood samples to obtain serum were collected at Cycle 1 Day 1(Baseline), Cycle 1 Day 8, Cycle 2 Days 1,8 \&15, Cycles 3 to 9,11,13 Day 1, Final Visit, and analyzed for CytoC concentration. Changes in CytoC concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included. For results reported as below quantifiable level (BQL), zero was used for calculating summary statistics. If more than 50% of the results at a visit were BQL, then only 'n', 'minimum' and 'maximum' were calculated for summary statistics.

    Time frame: Cycle 1 (Day 8), Cycle 2 (Days 1, 8 and 15), Cycles 3, 4, 5, 6, 7, 8, 9, 11, & 13 (Day 1), and Final Visit, up to data cutoff date 11 April 2011 (Cycle length= 28 days)

  7. Change From Baseline in Concentrations of M-30 Neo-Antigen

    Blood samples to obtain serum were collected at Cycle 1 Day 1(Baseline), Cycle 1 Day 8, Cycle 2 Days 1,8 \&15, Cycles 3 to 9,11,13 Day 1, Final Visit, and analyzed for M-30 concentration. Changes in M-30 concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included. For results reported as BQL, zero was used for calculating summary statistics. If more than 50% of the results at a visit were BQL, then only 'n', 'minimum' and 'maximum' were calculated for summary statistics.

    Time frame: Cycle 1 (Day 8), Cycle 2 (Days 1, 8 & 15), Cycles 3, 4, 5, 6, 7, 8, 9, 11 & 13 (Day 1) and Final Visit, up to data cutoff date 11 April 2011 (Cycle length= 28 days)

  8. Change From Baseline in Concentrations of Activated Caspase 3/7 (Casp 3/7)

    Blood samples to obtain serum were collected at Cycle 1 Day 1 (Baseline), Cycle 1 Day 8, Cycle 2 Days 1, 8, and 15, Cycles 3 to 9, 11, 13 (Day 1), Final Visit, and analyzed for Casp 3/7 concentration. Changes in Casp 3/7 concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included. The concentrations of Casp 3/7 were BQL for most participants at most time points. For results reported as BQL, zero was used for calculating summary statistics. If more than 50% of the results at a visit were BQL, then only 'n', 'minimum' and 'maximum' were calculated for summary statistics.

    Time frame: Cycle 1 (Day 8), Cycle 2 (Days 1, 8, & 15), Cycles 3, 4, 5, 6, 7, 8, 9, 11, & 13 (Day 1) and Final Visit, up to data cutoff date 11 April 2011 (Cycle length= 28 days)

  9. Duration of Response (DoR) Assessed as Per Independent Imaging Reviewers (IIR)

    DoR was based on IIR was the time from date of the first CR or PR until the date of first documentation of disease progression or date of death, if death occurred prior to disease progression, for the participants who had BOR of CR or PR. Participants without progressive disease or death were censored at the date of last adequate tumor assessment. Duration of response = End Date - Date of first CR or PR + 1

    Time frame: From date of the first CR or PR until the date of first documentation of disease progression or date of death, assessed up to data cutoff date 11 April 2011

  10. Disease Control Rate (DCR) Assessed as Per IIR

    DCR was the percentage of the participants who had BOR of CR, PR, and stable disease (SD) with the minimum duration of SD lasting greater than or equal to 7 weeks, based on assessments by IIR. DCR = CR+PR+SD greater than or equal to 7 weeks

    Time frame: From date of treatment start until disease progression, development of unacceptable toxicity, withdrawal of consent, participant's choice to stop study treatment, or up to data cutoff date 11 April 2011, for up to approximately 2 years 5 months

  11. Clinical Benefit Rate (CBR) Assessed as Per IIR

    CBR was the percentage of the participants who had BOR of CR, PR, and SD with the minimum duration of SD lasting greater than or equal to 23 weeks, based on assessments by IIR. CBR = CR+PR+SD greater than or equal to 23 weeks

    Time frame: From date of treatment start until disease progression, development of unacceptable toxicity, withdrawal of consent, participant's choice to stop study treatment, or up to data cutoff date 11 April 2011, for up to approximately 2 years 5 months

  12. Time to Response (TTR) Assessed as Per IIR

    TTR was defined as "time from start of treatment to the time when a participant first achieves a response of PR/CR" based on assessments by IIR. TTR was only calculated for participants with confirmed PR or CR.

    Time frame: From date of treatment start until date of first CR or PR, assessed up to data cutoff date 11 April 2011

  13. Progression Free Survival (PFS) Assessed as Per IIR

    PFS was defined as the time from the date of treatment start until progressive disease or death from any cause in the absence of progressive disease. Disease progression was defined as at least a 20% increase in the sum of the longest diameter of target lesions (taking as reference the smallest sum on study), recorded since the treatment started or the appearance of 1 or more new lesions as assessed by IIR using RECIST 1.0. The duration of PFS was calculated as end date minus date of first drug plus 1, based on assessments by IIR. PFS was calculated using Kaplan-Meier estimate and presented with 2-sided 95% Cl.

    Time frame: From date of treatment start until date of progressive disease or death from any cause, assessed up to data cutoff date 11 April 2011, for up to approximately 2 years 5 months

  14. Overall Survival (OS)

    OS was defined as the time from the date of treatment start until death from any cause. The duration of OS was calculated as 'end date minus date of first drug plus 1', based on assessments by IIR. Participants without a reported death or those lost to follow-up were censored at their last known alive date at the database cutoff. OS was calculated using Kaplan-Meier estimate and presented with 2-sided 95% Cl.

    Time frame: From date of treatment start until date of death from any cause, assessed up to data cutoff date 11 April 2011, for up to approximately 2 years 5 months

  15. Number of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability of Lenvatinib

    Safety assessments consisted of monitoring and recording all AEs (serious and non-serious) and SAEs; concomitant medications, regular monitoring of hematology, blood chemistry, and urine values; periodic measurement of vital signs, Eastern Cooperative Oncology Group (ECOG) performance status, New York Heart Association (NYHA) assessments, electrocardiograms (ECGs), echocardiograms; and performance of physical examinations.

    Time frame: For each participant, from the first dose till 30 days after the last dose of study treatment (up to approximately 10 years 4 months)

07

Results

Posted Aug 1, 2019

Participant flow

162 participants were screened for entry into the study, from which 45 were screening failures and 117 entered into the study and were treated.

Participant flow — Overall Study
MilestoneDTC CohortMTC Cohort
Started5859
Completed5859
Not completed00

Outcome measures

PrimaryObjective Response Rate (ORR)

ORR was the percentage of participants with best overall response (BOR) of complete response (CR) and partial response (PR) based on modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 for target lesions using magnetic resonance imaging/computed tomography (MRI/CT) scans, as determined by independent imaging review (IIR). CR was defined as disappearance of all target lesions. PR was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of the longest diameter. ORR=CR+PR, was presented with 2-sided 95% confidence interval (CI) by the method of Clopper and Pearson.

Time frame:
From date of treatment start until disease progression, development of unacceptable toxicity, withdrawal of consent, participant's choice to stop study treatment, or up to data cutoff date 11 April 2011, for up to approximately 2 years 5 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsDTC CohortMTC Cohort
Objective Response Rate (ORR)50.0 (36.6 to 63.4)35.6 (23.6 to 49.1)
PrimaryPlasma Pharmacokinetics (PK): Steady State Area Under the Plasma Concentration Curve (AUC)

Up to 9 samples per participant were obtained at specific time points. Plasma concentrations of lenvatinib were analyzed using standard analysis methods. Due to the sparse PK sampling in this study, the data were pooled with data from other Phase 1 studies conducted in participants with solid tumors for PK model development and covariate analysis. Individual exposure (steady state AUC) to lenvatinib in MTC and DTC subjects in this study was derived based on the individual predicted steady state AUC from the final PK model. Only data for participants taking 24 mg lenvatinib daily were reported (participants taking 20 mg lenvatinib daily were not included in this data set).

Time frame:
Cycle 1 Day 1 (predose and at 0.5 and 2 hours postdose), Cycle 1 Day 8 (predose), Cycle 2 Day 1 (predose and at 0.5 and 2 hours postdose), and Cycle 3 Day 1 (predose and at 2 hours postdose) (Cycle length= 28 days)
Reported as:
Median · ng·h/mL
Plasma Pharmacokinetics (PK): Steady State Area Under the Plasma Concentration Curve (AUC)
ng·h/mLDTC CohortMTC Cohort
Plasma Pharmacokinetics (PK): Steady State Area Under the Plasma Concentration Curve (AUC)3840 (1610 to 6960)3350 (1040 to 6840)
SecondaryChange From Baseline in Free Thyroxine (T4)

Blood samples to measure free T4 were collected at Screening (Baseline), Cycle 1 Day 15 (MTC cohort), Day 1 of Cycles 2 to 20, and Final Visit. Changes in free T4 concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included.

Time frame:
Day 1 or within 72 hours prior to Day 1 of Cycles 2 to 20, and Final Visit, up to data cutoff date 11 April 2011 (Cycle length= 28 days)
Reported as:
Mean · pmol/L
Change From Baseline in Free Thyroxine (T4)
pmol/LDTC CohortMTC Cohort
Cycle 1 Day 15—-3.80
Cycle 2 Day 1-0.46 ± 5.149-0.86 ± 3.913
Cycle 3 Day 1-0.92 ± 4.985-1.00 ± 4.028
Cycle 4 Day 1-1.05 ± 5.5810.34 ± 4.192
Cycle 5 Day 1-1.03 ± 5.563-0.46 ± 3.878
Cycle 6 Day 1-2.19 ± 5.373-0.17 ± 4.719
Cycle 7 Day 1-2.32 ± 5.098-1.07 ± 5.403
Cycle 8 Day 1-1.74 ± 5.504-1.13 ± 5.691
Cycle 9 Day 1-0.39 ± 5.2950.52 ± 5.213
Cycle 10 Day 1-0.26 ± 6.3971.33 ± 6.319
Cycle 11 Day 1-0.27 ± 6.3840.30 ± 5.551
Cycle 12 Day 1-1.60 ± 6.331-0.43 ± 5.380
Cycle 13 Day 1-0.09 ± 5.4160.07 ± 4.347
Cycle 14 Day 1-0.54 ± 5.772-0.82 ± 6.394
Cycle 15 Day 10.63 ± 6.703-1.01 ± 5.505
Cycle 16 Day 1-0.98 ± 7.1500.60 ± 4.142
Cycle 17 Day 11.20 ± 7.0750.45 ± 3.528
Cycle 18 Day 10.38 ± 4.6482.17 ± 4.831
Cycle 19 Day 1-0.65 ± 4.0423.25 ± 4.596
Cycle 20 Day 1—5.20
Final Visit/Study Termination-0.36 ± 6.1751.27 ± 4.584
SecondaryChange From Baseline in Free Thyroid Stimulating Hormone (TSH)

Blood samples to measure free TSH were collected at Screening (Baseline), Cycle 1 Day 15 (MTC cohort), Day 1 of Cycles 2 to 20, and Final Visit. Changes in free TSH concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included. For any free TSH result that was reported as \<0.008 mIU/L, 0.004 mIU/L was used for calculating summary statistics.

Time frame:
Day 1 or within 72 hours prior to Day 1 of Cycles 2 to 20, and Final Visit, up to data cutoff date 11 April 2011 (Cycle length= 28 days)
Reported as:
Mean · mIU/L
Change From Baseline in Free Thyroid Stimulating Hormone (TSH)
mIU/LDTC CohortMTC Cohort
Cycle 1 Day 15—2.8030
Cycle 2 Day 10.4779 ± 3.076664.1585 ± 7.34946
Cycle 3 Day 10.5161 ± 2.791225.5788 ± 13.76600
Cycle 4 Day 10.6296 ± 2.294202.8751 ± 6.50098
Cycle 5 Day 10.5024 ± 2.227213.7098 ± 6.60386
Cycle 6 Day 10.8603 ± 3.090793.9822 ± 10.65477
Cycle 7 Day 10.6660 ± 2.086088.4308 ± 22.51715
Cycle 8 Day 10.2118 ± 3.1632411.4131 ± 32.65896
Cycle 9 Day 10.1270 ± 3.530206.6620 ± 18.89412
Cycle 10 Day 1-0.3277 ± 2.871146.1934 ± 17.99762
Cycle 11 Day 1-0.2940 ± 3.281922.7928 ± 9.42343
Cycle 12 Day 10.3500 ± 5.439465.1879 ± 14.81415
Cycle 13 Day 1-0.2799 ± 3.315182.0983 ± 7.03903
Cycle 14 Day 1-0.6232 ± 3.099549.6490 ± 32.48910
Cycle 15 Day 1-0.5911 ± 3.214470.9955 ± 4.93549
Cycle 16 Day 1-0.3396 ± 3.689030.2971 ± 3.33103
Cycle 17 Day 1-1.0352 ± 3.922867.4624 ± 16.18545
Cycle 18 Day 10.0331 ± 0.245204.1232 ± 7.01461
Cycle 19 Day 10.7805 ± 1.87674-0.2080 ± 0.29698
Cycle 20 Day 1—0.0000
Final Visit/Study Termination1.0281 ± 2.071613.4905 ± 7.39625
SecondaryPercent Change From Baseline in Concentrations of Thyroglobulin (DTC Only)

Blood samples to obtain serum were collected at Cycle 1 Day 1 (Baseline), Day 1 of Cycles 2 to 19, Final Visit, and were analyzed for thyroglobulin concentration. Percent changes in thyroglobulin concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included.

Time frame:
Day 1 or within 72 hours prior to Day 1 of Cycles 2 to 19, and Final Visit, up to data cutoff date 11 April 2011 (Cycle length= 28 days)
Reported as:
Mean · percent change
Percent Change From Baseline in Concentrations of Thyroglobulin (DTC Only)
percent changeDTC Cohort
Cycle 2 Day 1-62.21 ± 39.997
Cycle 3 Day 1-77.80 ± 22.278
Cycle 4 Day 1-79.25 ± 26.639
Cycle 5 Day 1-76.00 ± 25.085
Cycle 6 Day 1-20.36 ± 373.190
Cycle 7 Day 1-73.38 ± 45.489
Cycle 8 Day 1-79.96 ± 27.461
Cycle 9 Day 1-73.98 ± 31.366
Cycle 10 Day 1-78.26 ± 25.524
Cycle 11 Day 1-75.54 ± 37.327
Cycle 12 Day 1-73.51 ± 46.397
Cycle 13 Day 1-74.05 ± 37.091
Cycle 14 Day 1-78.70 ± 17.348
Cycle 15 Day 1-80.28 ± 16.029
Cycle 16 Day 1-76.38 ± 27.736
Cycle 17 Day 1-62.99 ± 38.740
Cycle 18 Day 1-72.67 ± 27.226
Cycle 19 Day 1-50.65 ± 46.900
Final Visit/Study Termination-68.60
SecondaryPercent Change From Baseline in Concentrations of Calcitonin (MTC Only)

Blood samples to obtain serum were collected at Cycle 1 Day 1(Baseline), Day 1 of Cycles 2 to 20, Final Visit, and were analyzed for calcitonin concentration. Percent changes in calcitonin concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included.

Time frame:
Day 1 or within 72 hours prior to Day 1 of Cycles 2 to 20, and Final Visit, up to data cutoff date 11 April 2011 (Cycle length= 28 days)
Reported as:
Mean · percent change
Percent Change From Baseline in Concentrations of Calcitonin (MTC Only)
percent changeMTC Cohort
Cycle 2 Day 1-42.27 ± 38.754
Cycle 3 Day 1-48.11 ± 30.976
Cycle 4 Day 1-44.54 ± 38.794
Cycle 5 Day 1-49.97 ± 34.634
Cycle 6 Day 1-41.73 ± 46.653
Cycle 7 Day 1-38.18 ± 62.721
Cycle 8 Day 1-47.29 ± 46.101
Cycle 9 Day 1-37.52 ± 72.588
Cycle 10 Day 1-39.57 ± 60.118
Cycle 11 Day 1-42.68 ± 61.797
Cycle 12 Day 1-29.25 ± 105.440
Cycle 13 Day 1-36.26 ± 89.612
Cycle 14 Day 1-18.16 ± 148.928
Cycle 15 Day 1-65.26 ± 24.553
Cycle 16 Day 1-64.24 ± 30.394
Cycle 17 Day 1-66.03 ± 23.777
Cycle 18 Day 1-64.57 ± 27.982
Cycle 19 Day 1-44.30 ± 18.668
Cycle 20 Day 1-29.40
Final Visit/Study Termination-36.70 ± 28.296
SecondaryPercent Change From Baseline in Concentrations of Carcinoembryonic Antigen (CEA) (MTC Only)

Blood samples were collected at Cycle 1 Day 1(Baseline), Day 1 of Cycles 2 to 20, Final Visit, and were analyzed for CEA concentration. Percent changes in CEA concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included.

Time frame:
Day 1 or within 72 hours prior to Day 1 of Cycles 2 to 20, and Final Visit, up to data cutoff date 11 April 2011 (Cycle length= 28 days)
Reported as:
Mean · percent change
Percent Change From Baseline in Concentrations of Carcinoembryonic Antigen (CEA) (MTC Only)
percent changeMTC Cohort
Cycle 2 Day 1-26.07 ± 45.864
Cycle 3 Day 1-37.68 ± 42.236
Cycle 4 Day 1-41.49 ± 48.035
Cycle 5 Day 1-44.62 ± 42.138
Cycle 6 Day 1-41.91 ± 47.388
Cycle 7 Day 1-41.39 ± 45.677
Cycle 8 Day 1-42.89 ± 47.818
Cycle 9 Day 1-49.31 ± 32.185
Cycle 10 Day 1-47.35 ± 31.621
Cycle 11 Day 1-51.75 ± 29.671
Cycle 12 Day 1-49.91 ± 32.597
Cycle 13 Day 1-46.44 ± 35.967
Cycle 14 Day 1-47.98 ± 38.324
Cycle 15 Day 1-56.62 ± 34.051
Cycle 16 Day 1-59.83 ± 34.762
Cycle 17 Day 1-53.80 ± 37.981
Cycle 18 Day 1-46.00 ± 39.905
Cycle 19 Day 1-45.65 ± 18.738
Cycle 20 Day 1-61.40
Final Visit/Study Termination-29.43 ± 31.453
SecondaryChange From Baseline in Concentrations of Cytochrome C (CytoC)

Blood samples to obtain serum were collected at Cycle 1 Day 1(Baseline), Cycle 1 Day 8, Cycle 2 Days 1,8 \&15, Cycles 3 to 9,11,13 Day 1, Final Visit, and analyzed for CytoC concentration. Changes in CytoC concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included. For results reported as below quantifiable level (BQL), zero was used for calculating summary statistics. If more than 50% of the results at a visit were BQL, then only 'n', 'minimum' and 'maximum' were calculated for summary statistics.

Time frame:
Cycle 1 (Day 8), Cycle 2 (Days 1, 8 and 15), Cycles 3, 4, 5, 6, 7, 8, 9, 11, & 13 (Day 1), and Final Visit, up to data cutoff date 11 April 2011 (Cycle length= 28 days)
Reported as:
Mean · pg/mL
Change From Baseline in Concentrations of Cytochrome C (CytoC)
pg/mLDTC CohortMTC Cohort
Cycle 1 Day 8155.57 ± 825.091502.84 ± 2146.291
Cycle 2 Day 1—1679.40
Cycle 2 Day 8-218.45 ± 591.217374.46 ± 2279.207
Cycle 2 Day 15-215.50—
Cycle 3 Day 1-175.43 ± 435.635311.85 ± 2363.970
Cycle 4 Day 11.38 ± 268.35463.01 ± 1738.149
Cycle 5 Day 1-21.32 ± 85.4691078.85 ± 3793.235
Cycle 6 Day 1721.58 ± 1234.2151411.29 ± 3855.502
Cycle 7 Day 1858.05 ± 1383.9622184.30 ± 4689.181
Cycle 8 Day 11358.51 ± 1364.706451.36 ± 254.305
Cycle 9 Day 11356.40 ± 913.685459.38 ± 1572.717
Cycle 11 Day 1139.60—
Cycle 13 Day 1129.60—
Final Visit/Study Termination249.31 ± 765.148-45.97 ± 1294.476
SecondaryChange From Baseline in Concentrations of M-30 Neo-Antigen

Blood samples to obtain serum were collected at Cycle 1 Day 1(Baseline), Cycle 1 Day 8, Cycle 2 Days 1,8 \&15, Cycles 3 to 9,11,13 Day 1, Final Visit, and analyzed for M-30 concentration. Changes in M-30 concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included. For results reported as BQL, zero was used for calculating summary statistics. If more than 50% of the results at a visit were BQL, then only 'n', 'minimum' and 'maximum' were calculated for summary statistics.

Time frame:
Cycle 1 (Day 8), Cycle 2 (Days 1, 8 & 15), Cycles 3, 4, 5, 6, 7, 8, 9, 11 & 13 (Day 1) and Final Visit, up to data cutoff date 11 April 2011 (Cycle length= 28 days)
Reported as:
Mean · U/L
Change From Baseline in Concentrations of M-30 Neo-Antigen
U/LDTC CohortMTC Cohort
Cycle 1 Day 8-5.22 ± 108.63946.32 ± 197.509
Cycle 2 Day 1—-77.80
Cycle 2 Day 8-26.41 ± 257.723-49.33 ± 289.525
Cycle 2 Day 1535.30—
Cycle 3 Day 119.70 ± 296.010-90.21 ± 314.343
Cycle 4 Day 1-7.89 ± 336.124-97.53 ± 296.832
Cycle 5 Day 1-24.83 ± 397.337-161.36 ± 265.548
Cycle 6 Day 1-99.30 ± 321.554-161.30 ± 214.299
Cycle 7 Day 1-168.50 ± 378.071-52.79 ± 129.671
Cycle 8 Day 1-180.22 ± 386.682-92.44 ± 57.828
Cycle 9 Day 1-111.92 ± 189.411-85.22 ± 161.751
Cycle 11 Day 155.00—
Cycle 13 Day 1-263.50—
Final Visit/Study Termination-151.73 ± 322.159-158.99 ± 355.903
SecondaryChange From Baseline in Concentrations of Activated Caspase 3/7 (Casp 3/7)

Blood samples to obtain serum were collected at Cycle 1 Day 1 (Baseline), Cycle 1 Day 8, Cycle 2 Days 1, 8, and 15, Cycles 3 to 9, 11, 13 (Day 1), Final Visit, and analyzed for Casp 3/7 concentration. Changes in Casp 3/7 concentration values from baseline to specific time points were calculated. Only participants with both baseline and relevant visit values were included. The concentrations of Casp 3/7 were BQL for most participants at most time points. For results reported as BQL, zero was used for calculating summary statistics. If more than 50% of the results at a visit were BQL, then only 'n', 'minimum' and 'maximum' were calculated for summary statistics.

Time frame:
Cycle 1 (Day 8), Cycle 2 (Days 1, 8, & 15), Cycles 3, 4, 5, 6, 7, 8, 9, 11, & 13 (Day 1) and Final Visit, up to data cutoff date 11 April 2011 (Cycle length= 28 days)
Reported as:
Mean · U/W
Change From Baseline in Concentrations of Activated Caspase 3/7 (Casp 3/7)
U/WDTC CohortMTC Cohort
Cycle 1 Day 8NA ± NA0.0030 ± 0.00610
Cycle 2 Day 1—0.0080
Cycle 2 Day 8NA ± NA0.0039 ± 0.00822
Cycle 2 Day 150.0110—
Cycle 3 Day 1NA ± NA0.0026 ± 0.00691
Cycle 4 Day 1NA ± NA0.0019 ± 0.00743
Cycle 5 Day 1NA ± NA0.0042 ± 0.00666
Cycle 6 Day 10.0046 ± 0.00605NA ± NA
Cycle 7 Day 10.0058 ± 0.004960.0044 ± 0.00692
Cycle 8 Day 10.0078 ± 0.00771NA ± NA
Cycle 9 Day 10.0067 ± 0.004800.0068 ± 0.01329
Cycle 11 Day 1NA ± NA—
Cycle 13 Day 1NA ± NA—
Final Visit/Study TerminationNA ± NANA ± NA
SecondaryDuration of Response (DoR) Assessed as Per Independent Imaging Reviewers (IIR)

DoR was based on IIR was the time from date of the first CR or PR until the date of first documentation of disease progression or date of death, if death occurred prior to disease progression, for the participants who had BOR of CR or PR. Participants without progressive disease or death were censored at the date of last adequate tumor assessment. Duration of response = End Date - Date of first CR or PR + 1

Time frame:
From date of the first CR or PR until the date of first documentation of disease progression or date of death, assessed up to data cutoff date 11 April 2011
Reported as:
Median · Months
Duration of Response (DoR) Assessed as Per Independent Imaging Reviewers (IIR)
MonthsDTC CohortMTC Cohort
Duration of Response (DoR) Assessed as Per Independent Imaging Reviewers (IIR)12.7 (8.8 to NA)NA (5.7 to NA)
SecondaryDisease Control Rate (DCR) Assessed as Per IIR

DCR was the percentage of the participants who had BOR of CR, PR, and stable disease (SD) with the minimum duration of SD lasting greater than or equal to 7 weeks, based on assessments by IIR. DCR = CR+PR+SD greater than or equal to 7 weeks

Time frame:
From date of treatment start until disease progression, development of unacceptable toxicity, withdrawal of consent, participant's choice to stop study treatment, or up to data cutoff date 11 April 2011, for up to approximately 2 years 5 months
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR) Assessed as Per IIR
Percentage of participantsDTC CohortMTC Cohort
Disease Control Rate (DCR) Assessed as Per IIR93.1 (83.3 to 98.1)79.7 (67.2 to 89.0)
SecondaryClinical Benefit Rate (CBR) Assessed as Per IIR

CBR was the percentage of the participants who had BOR of CR, PR, and SD with the minimum duration of SD lasting greater than or equal to 23 weeks, based on assessments by IIR. CBR = CR+PR+SD greater than or equal to 23 weeks

Time frame:
From date of treatment start until disease progression, development of unacceptable toxicity, withdrawal of consent, participant's choice to stop study treatment, or up to data cutoff date 11 April 2011, for up to approximately 2 years 5 months
Reported as:
Number · Percentage of participants
Clinical Benefit Rate (CBR) Assessed as Per IIR
Percentage of participantsDTC CohortMTC Cohort
Clinical Benefit Rate (CBR) Assessed as Per IIR77.6 (64.7 to 87.5)64.4 (50.9 to 76.4)
SecondaryTime to Response (TTR) Assessed as Per IIR

TTR was defined as "time from start of treatment to the time when a participant first achieves a response of PR/CR" based on assessments by IIR. TTR was only calculated for participants with confirmed PR or CR.

Time frame:
From date of treatment start until date of first CR or PR, assessed up to data cutoff date 11 April 2011
Reported as:
Median · Months
Time to Response (TTR) Assessed as Per IIR
MonthsDTC CohortMTC Cohort
Time to Response (TTR) Assessed as Per IIR3.6 (1.8 to 3.7)3.5 (1.9 to 3.7)
SecondaryProgression Free Survival (PFS) Assessed as Per IIR

PFS was defined as the time from the date of treatment start until progressive disease or death from any cause in the absence of progressive disease. Disease progression was defined as at least a 20% increase in the sum of the longest diameter of target lesions (taking as reference the smallest sum on study), recorded since the treatment started or the appearance of 1 or more new lesions as assessed by IIR using RECIST 1.0. The duration of PFS was calculated as end date minus date of first drug plus 1, based on assessments by IIR. PFS was calculated using Kaplan-Meier estimate and presented with 2-sided 95% Cl.

Time frame:
From date of treatment start until date of progressive disease or death from any cause, assessed up to data cutoff date 11 April 2011, for up to approximately 2 years 5 months
Reported as:
Median · Months
Progression Free Survival (PFS) Assessed as Per IIR
MonthsDTC CohortMTC Cohort
Progression Free Survival (PFS) Assessed as Per IIR12.6 (9.9 to 16.1)9.0 (7.0 to NA)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of treatment start until death from any cause. The duration of OS was calculated as 'end date minus date of first drug plus 1', based on assessments by IIR. Participants without a reported death or those lost to follow-up were censored at their last known alive date at the database cutoff. OS was calculated using Kaplan-Meier estimate and presented with 2-sided 95% Cl.

Time frame:
From date of treatment start until date of death from any cause, assessed up to data cutoff date 11 April 2011, for up to approximately 2 years 5 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsDTC CohortMTC Cohort
Overall Survival (OS)27.7 (27.7 to NA)16.6 (16.4 to NA)
SecondaryNumber of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability of Lenvatinib

Safety assessments consisted of monitoring and recording all AEs (serious and non-serious) and SAEs; concomitant medications, regular monitoring of hematology, blood chemistry, and urine values; periodic measurement of vital signs, Eastern Cooperative Oncology Group (ECOG) performance status, New York Heart Association (NYHA) assessments, electrocardiograms (ECGs), echocardiograms; and performance of physical examinations.

Time frame:
For each participant, from the first dose till 30 days after the last dose of study treatment (up to approximately 10 years 4 months)
Reported as:
Number · Participants
Number of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability of Lenvatinib
ParticipantsDTC CohortMTC Cohort
Non-Serious AEs5859
SAEs3242

Adverse events

Collected over For each participant, from the first dose till 30 days after the last dose of study treatment (up to approximately 10 years 4 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DTC Cohort44/58 (75.9%)32/58 (55.2%)58/58 (100%)
MTC Cohort37/59 (62.7%)42/59 (71.2%)59/59 (100%)
Most frequent serious events
Showing 10 of 129
Most frequent serious events
EventDTC CohortMTC Cohort
Pulmonary embolismRespiratory, thoracic and mediastinal disorders4/583/59
DehydrationMetabolism and nutrition disorders4/583/59
HypotensionVascular disorders4/581/59
PneumoniaInfections and infestations2/584/59
Abdominal painGastrointestinal disorders0/583/59
Decreased appetiteMetabolism and nutrition disorders1/583/59
Lung infectionInfections and infestations0/583/59
AmenorrhoeaReproductive system and breast disorders0/583/59
Abdominal pain lowerGastrointestinal disorders2/580/59
HypertensionVascular disorders2/581/59
Most frequent other events
Showing 10 of 191
Most frequent other events
EventDTC CohortMTC Cohort
HypertensionVascular disorders45/5831/59
DiarrhoeaGastrointestinal disorders40/5845/59
ProteinuriaRenal and urinary disorders41/5838/59
Weight decreasedInvestigations39/5829/59
FatigueGeneral disorders35/5833/59
Decreased appetiteMetabolism and nutrition disorders32/5832/59
NauseaGastrointestinal disorders30/5830/59
CoughRespiratory, thoracic and mediastinal disorders28/5824/59
HeadacheNervous system disorders27/5827/59
DysphoniaRespiratory, thoracic and mediastinal disorders25/5820/59

Baseline characteristics

Intent-to-treat population included all participants who received at least one dose of the study drug and was the primary analysis set for efficacy analyses.

Age, Continuous
Age, Continuous(Years)DTC CohortMTC CohortTotal
Mean60.9 ± 9.4951.6 ± 14.1156.2 ± 12.88
Sex: Female, Male
Sex: Female, Male(Participants)DTC CohortMTC CohortTotal
Female242246
Male343771
08

Study locations

42 sites
  • Little Rock, Arkansas, United States
  • Los Angeles, California, United States
  • Los Gatos, California, United States
  • Mission Viejo, California, United States
  • Santa Monica, California, United States
  • Torrance, California, United States
  • Aurora, Colorado, United States
  • Orlando, Florida, United States
  • Tampa, Florida, United States
  • Roswell, Georgia, United States
  • Chicago, Illinois, United States
  • Baltimore, Maryland, United States
  • Bethesda, Maryland, United States
  • Boston, Massachusetts, United States
  • Minneapolis, Minnesota, United States
  • Columbia, Missouri, United States
  • Jefferson City, Missouri, United States
  • Lebanon, New Hampshire, United States
  • Montclair, New Jersey, United States
  • Houston, Texas, United States
  • Long Beach, Washington, United States
  • Seattle, Washington, United States
  • Madison, Wisconsin, United States
  • St Leonards, New South Wales, Australia
  • Brisbane, Australia
  • Melbourne, Australia
  • Lyon, France
  • Paris, France
  • Reims, France
  • Villejuif Cedex, France
  • Ferrara, Italy
  • Milan, Italy
  • Naples, Italy
  • Pisa, Italy
  • Rome, Italy
  • Siena, Italy
  • Gliwice, Poland
  • Poznan, Poland
  • Cardiff, United Kingdom
  • Glasgow, United Kingdom
  • London, United Kingdom
  • Sutton, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2008 to primary completion in Apr 2011, 29 months.

Results were first posted in Aug 2019, 8 years 3 months after primary completion.

Of 92 phase 2 interventional studies under Thyroid Neoplasms, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 119. This study's 29 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2008
First posted
Nov 2, 2008
StartActual
Nov 6, 2008
Primary completionActual
Apr 11, 2011
CompletionActual
Mar 29, 2019
Results first posted
Aug 1, 2019
Last update
Apr 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00784303
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Nov 2, 2008
Start date
Nov 6, 2008
Primary completion
Apr 11, 2011
Completion
Mar 29, 2019
Results posted
Aug 1, 2019
Last update
Apr 22, 2020

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion